Literature DB >> 21612813

RUNX3 functions as an oncogene in ovarian cancer.

Cecilia Wei Lin Lee1, Linda Shyue Huey Chuang, Shunichi Kimura, Soak Kuan Lai, Chee Wee Ong, Benedict Yan, Manuel Salto-Tellez, Mahesh Choolani, Yoshiaki Ito.   

Abstract

OBJECTIVE: The Runt domain transcription factor, RUNX3, has been shown to be a tumor suppressor in a variety of cancers including gastric, colon and breast cancer. Interestingly, an oncogenic role for RUNX3 has also been suggested in basal cell carcinoma and head and neck cancer. Here, we explore the role of RUNX3 in ovarian cancer.
METHODS: Expression of RUNX3 mRNA and protein was evaluated in human ovarian cancer cell lines. In addition, subcellular localization of RUNX3 was also examined in cell lines and ovarian cancer tissues. Effect of exogenous RUNX3 expression and knockdown on cell proliferation was investigated by proliferation assays and a soft agar assay.
RESULTS: Expression of RUNX3 was detected in the nucleus of ovarian cancer cell lines and ovarian cancer tissues and was found to play a growth stimulatory role. RUNX3 knockdown resulted in a decrease in cell proliferation in liquid media as well as in soft agar. Despite the fact that exogenous expression of RUNX3 strongly inhibits cell growth in many cell types, RUNX3 promoted cell growth in ovarian cancer cell lines not expressing RUNX3.
CONCLUSION: RUNX3 is frequently expressed in the nuclei of ovarian cancer cell lines and plays an oncogenic role in ovarian cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21612813     DOI: 10.1016/j.ygyno.2011.04.044

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  29 in total

1.  Investigation of methylation and protein expression of the Runx3 gene in colon carcinogenesis.

Authors:  Shao-Ya He; Ren-Fa Jiang; Jie Jiang; Yang-Sheng Xiang; Ling Wang
Journal:  Biomed Rep       Date:  2015-06-17

2.  RUNX3 expression is associated with sensitivity to pheophorbide a-based photodynamic therapy in keloids.

Authors:  Zhenlong Zheng; Lianhua Zhu; Xianglan Zhang; Lianhua Li; Sook Moon; Mi Ryung Roh; Zhehu Jin
Journal:  Lasers Med Sci       Date:  2014-06-24       Impact factor: 3.161

3.  The roles of RUNX3 in cervical cancer cells in vitro.

Authors:  Zhen Li; Pan Fan; Min Deng; Chao Zeng
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

4.  Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.

Authors:  A Kumar; M Singhal; C Chopra; S Srinivasan; R P Surabhi; R Kanumuri; S Tentu; S Jagadeeshan; S Sundaram; K Ramanathan; R Shankar Pitani; B Muthuswamy; S Abhijit; A S Nair; G Venkatraman; S K Rayala
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

Review 5.  The RUNX family: developmental regulators in cancer.

Authors:  Yoshiaki Ito; Suk-Chul Bae; Linda Shyue Huey Chuang
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

6.  RUNX3 facilitates growth of Ewing sarcoma cells.

Authors:  Krista L Bledsoe; Meghan E McGee-Lawrence; Emily T Camilleri; Xiaoke Wang; Scott M Riester; Andre J van Wijnen; Andre M Oliveira; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

7.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

8.  RUNX3 confers sensitivity to pheophorbide a-photodynamic therapy in human oral squamous cell carcinoma cell lines.

Authors:  Sook Moon; Jung Yoon Bae; Hwa-Kyung Son; Doo Young Lee; Gyeongju Park; Hyun You; Hyojin Ko; Yong-Chul Kim; Jin Kim
Journal:  Lasers Med Sci       Date:  2013-05-23       Impact factor: 3.161

9.  Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: implications in molecular imaging.

Authors:  Yixuan Yang; Weiyi Toy; Lee Yee Choong; Peiling Hou; Hassan Ashktorab; Duane T Smoot; Khay Guan Yeoh; Yoon Pin Lim
Journal:  J Proteome Res       Date:  2012-11-26       Impact factor: 4.466

10.  Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma.

Authors:  Zhe Jin; Ya-Xin Han; Xiao-Rui Han
Journal:  J Mol Histol       Date:  2013-05-12       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.